
Dinesh Khanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7857016/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
3	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	2.8	1,467
4	Systemic sclerosis. Lancet, The, 2017, 390, 1685-1699.	13.7	1,423
5	2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseaseâ€modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	3.4	1,413
6	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	3.4	1,268
7	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
8	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
9	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
10	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
11	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	10.7	754
12	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.9	657
13	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Annals of the Rheumatic Diseases, 2014, 73, 1340-1349.	0.9	633
14	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	3.4	598
15	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	13.7	505
16	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	3.4	420
17	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine, 2018, 378, 35-47.	27.0	417
18	Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415

#	Article	IF	CITATIONS
19	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1026-1034.	5.6	411
20	Distinctions Between Diagnostic and Classification Criteria?. Arthritis Care and Research, 2015, 67, 891-897.	3.4	386
21	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
22	Diagnosis of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801904.	6.7	333
23	Natural products as a gold mine for arthritis treatment. Current Opinion in Pharmacology, 2007, 7, 344-351.	3.5	326
24	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.7	321
25	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis and Rheumatology, 2020, 72, 879-895.	5.6	302
26	Methods of Formal Consensus in Classification/Diagnostic Criteria and Guideline Development. Seminars in Arthritis and Rheumatism, 2011, 41, 95-105.	3.4	290
27	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246
28	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the Rheumatic Diseases, 2018, 77, 212-220.	0.9	236
29	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	2.0	222
30	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. American Journal of Gastroenterology, 2014, 109, 1804-1814.	0.4	190
31	Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis and Rheumatism, 2009, 61, 1257-1263.	6.7	186
32	Safety of Tumour Necrosis Factor-?? Antagonists. Drug Safety, 2004, 27, 307-324.	3.2	183
33	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
34	Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 3194-3201.	6.7	175
35	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€Initiated, Multicenter, Doubleâ€Blind, Randomized, Placebo ontrolled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	5.6	163
36	Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy. Ophthalmology, 2010, 117, 133-139.e2.	5.2	159

#	Article	IF	CITATIONS
37	Atherosclerosis in systemic sclerosis: A systematic review and meta-analysis. Arthritis and Rheumatism, 2011, 63, 2078-2090.	6.7	152
38	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health and Quality of Life Outcomes, 2012, 10, 117.	2.4	152
39	Item Response Theory, Computerized Adaptive Testing, and PROMIS: Assessment of Physical Function. Journal of Rheumatology, 2014, 41, 153-158.	2.0	149
40	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Annals of the Rheumatic Diseases, 2015, 74, 1612-1620.	0.9	148
41	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group. Journal of Rheumatology, 2015, 42, 2168-2171.	2.0	142
42	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases, 2019, 78, 122-130.	0.9	141
43	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2009, 60, 1102-1111.	6.7	137
44	Survival and Predictors of Mortality in Systemic Sclerosisâ€Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care and Research, 2014, 66, 489-495.	3.4	132
45	Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. Chest, 2009, 136, 1333-1340.	0.8	127
46	A oneâ€year, phase I/IIa, openâ€label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease. Arthritis and Rheumatism, 2011, 63, 3540-3546.	6.7	125
47	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis and Rheumatology, 2017, 69, 1903-1913.	5.6	124
48	Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 3016-3026.	5.6	123
49	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 1362-1371.	0.9	122
50	Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. Arthritis and Rheumatism, 2005, 52, 592-600.	6.7	120
51	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	10.7	118
52	The future of measuring patientâ€reported outcomes in rheumatology: Patientâ€Reported Outcomes Measurement Information System (PROMIS). Arthritis Care and Research, 2011, 63, S486-90.	3.4	115
53	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism, 2014, 43, 666-672.	3.4	115
54	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	5.6	110

#	Article	IF	CITATIONS
55	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
56	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis and Rheumatology, 2017, 69, 1451-1460.	5.6	109
57	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis and Rheumatism, 2011, 63, 3078-3085.	6.7	107
58	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology, 2005, 32, 832-40.	2.0	107
59	Gastrointestinal manifestations of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 247-256.	1.7	106
60	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. Journal of Clinical Investigation, 2020, 130, 2451-2464.	8.2	106
61	Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, doubleâ€blind, randomized controlled trials. Arthritis and Rheumatism, 2009, 60, 2490-2498.	6.7	105
62	Predicting treatment outcomes and responder subsets in sclerodermaâ€related interstitial lung disease. Arthritis and Rheumatism, 2011, 63, 2797-2808.	6.7	105
63	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 650-660.	5.6	105
64	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	1.9	104
65	Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 1301-1310.	5.6	104
66	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology, 2013, 52, 1809-1817.	1.9	101
67	Perceptions of disease and health-related quality of life among patients with gout. Rheumatology, 2008, 48, 582-586.	1.9	100
68	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	5.6	100
69	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the Rheumatic Diseases, 2020, 79, 379-386.	0.9	97
70	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the Rheumatic Diseases, 2015, 74, 1124-1131.	0.9	96
71	Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. American Journal of Gastroenterology, 2018, 113, 1701-1710.	0.4	96
72	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis, IAMA - Iournal of the American Medical Association, 2016, 315, 1975.	7.4	95

#	Article	IF	CITATIONS
73	Early detection and management of pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 306-312.	7.1	94
74	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis and Rheumatism, 2007, 56, 1676-1684.	6.7	93
75	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor–Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 480-486.	2.5	92
76	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 209-221.	5.6	88
77	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials. Arthritis Research and Therapy, 2015, 17, 372.	3.5	87
78	Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, singleâ€blind pilot study. Arthritis and Rheumatism, 2009, 60, 3821-3830.	6.7	86
79	The Minimally Important Difference for the Fatigue Visual Analog Scale in Patients with Rheumatoid Arthritis Followed in an Academic Clinical Practice. Journal of Rheumatology, 2008, 35, 2339-2343.	2.0	85
80	Management of connective tissue diseases associated interstitial lung disease. Current Opinion in Rheumatology, 2016, 28, 236-245.	4.3	85
81	Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Annals of the Rheumatic Diseases, 2013, 72, 1469-1474.	0.9	83
82	Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology, 2014, 53, 1172-1177.	1.9	83
83	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Annals of the Rheumatic Diseases, 2012, 71, 1335-1342.	0.9	82
84	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology, 2011, 50, 740-745.	1.9	79
85	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 2019, 78, 648-656.	0.9	79
86	Clinical and serological features of systemic sclerosis in a multicenter African American cohort. Medicine (United States), 2017, 96, e8980.	1.0	78
87	Validation of potential classification criteria for systemic sclerosis. Arthritis Care and Research, 2012, 64, 358-367.	3.4	77
88	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). American Journal of Respiratory and Critical Care Medicine, 2018, 197, 644-652.	5.6	77
89	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proceedings of the United States of America, 2019, 116, 3695-3702.	7.1	77
90	Articular involvement in systemic sclerosis. Rheumatology, 2012, 51, 1347-1356.	1.9	76

#	Article	IF	CITATIONS
91	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 374-381.	0.9	76
92	Exerciseâ€induced pulmonary hypertension associated with systemic sclerosis: Four distinct entities. Arthritis and Rheumatism, 2010, 62, 3741-3750.	6.7	74
93	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. Annals of the American Thoracic Society, 2018, 15, 1286-1295.	3.2	74
94	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 1634-1643.	5.6	74
95	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. Journal of Rheumatology, 2014, 41, 99-105.	2.0	73
96	Treatment of acute gout: A systematic review. Seminars in Arthritis and Rheumatism, 2014, 44, 31-38.	3.4	73
97	<i>IRF5</i> polymorphism predicts prognosis in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1197-1202.	0.9	72
98	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest, 2018, 154, 862-871.	0.8	72
99	Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. Journal of Rheumatology, 2007, 34, 1459-64.	2.0	72
100	Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life. Journal of Rheumatology, 2008, 35, 2406-2414.	2.0	71
101	Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial. Journal of Rheumatology, 2012, 39, 1326-1333.	2.0	71
102	Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. American Journal of Physiology - Cell Physiology, 2014, 307, C2-C13.	4.6	71
103	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.9	71
104	Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice. Arthritis and Rheumatology, 2022, 74, 13-27.	5.6	71
105	A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls. Arthritis and Rheumatism, 2008, 59, 591-597.	6.7	70
106	Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology, 2011, 50, 330-334.	1.9	70
107	Feasibility and Construct Validity of PROMIS and "Legacy―Instruments in an Academic Scleroderma Clinic. Value in Health, 2012, 15, 128-134.	0.3	70
108	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism, 2014, 44, 55-62.	3.4	69

#	Article	IF	CITATIONS
109	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2020, 79, 1600-1607.	0.9	69
110	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. Journal of Rheumatology, 2013, 40, 455-460.	2.0	67
111	Management of systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology, 2019, 31, 241-249.	4.3	67
112	Management of Gastrointestinal Involvement in Scleroderma. Current Treatment Options in Rheumatology, 2015, 1, 82-105.	1.4	64
113	Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Annals of the American Thoracic Society, 2016, 13, 793-802.	3.2	64
114	Systemic sclerosis - continuing progress in developing clinical measures of response. Journal of Rheumatology, 2007, 34, 1194-200.	2.0	64
115	Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis and Rheumatism, 2007, 57, 1280-1286.	6.7	63
116	Evidence-based management of rapidly progressing systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 387-400.	3.3	63
117	Health-related quality of lifean introduction. American Journal of Managed Care, 2007, 13 Suppl 9, S218-23.	1.1	63
118	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. Arthritis and Rheumatology, 2016, 68, 2975-2985.	5.6	62
119	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.7	62
120	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax, 2014, 69, 123-129.	5.6	61
121	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Annals of the Rheumatic Diseases, 2011, 70, 996-1002.	0.9	60
122	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	3.4	60
123	Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials. Journal of Rheumatology, 2012, 39, 1450-1457.	2.0	59
124	Points to consider for skin ulcers in systemic sclerosis. Rheumatology, 2017, 56, v67-v71.	1.9	59
125	Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis and Rheumatism, 2007, 57, 440-447.	6.7	58
126	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Research and Therapy, 2016, 18, 305.	3.5	58

#	Article	IF	CITATIONS
127	Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 2007, 16, 1083-1092.	3.1	57
128	Outcome measures in systemic sclerosis: An update on instruments and current research. Current Rheumatology Reports, 2007, 9, 151-157.	4.7	57
129	Measuring response in the gastrointestinal tract in systemic sclerosis. Current Opinion in Rheumatology, 2013, 25, 700-706.	4.3	57
130	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 674-684.	5.6	57
131	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis and Rheumatology, 2019, 71, 2059-2067.	5.6	55
132	Improved Cough and Cough-Specific QualityÂof Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease. Chest, 2017, 151, 813-820.	0.8	54
133	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. Arthritis Care and Research, 2018, 70, 1373-1384.	3.4	54
134	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1339-1349.	5.6	54
135	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. Current Treatment Options in Rheumatology, 2016, 2, 252-269.	1.4	53
136	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo ontrolled Trials. Arthritis Care and Research, 2018, 70, 439-444.	3.4	53
137	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	1.9	53
138	The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Annals of the Rheumatic Diseases, 2010, 69, 588-591.	0.9	52
139	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
140	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764.	3.1	52
141	<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 552-562.	7.1	52
142	Health values of patients with systemic sclerosis. Arthritis and Rheumatism, 2007, 57, 86-93.	6.7	51
143	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	1.9	51
144	Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease. Rheumatology, 2019, 58, 567-579.	1.9	51

#	Article	IF	CITATIONS
145	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.9	51
146	Gout disease-specific quality of life and the association with gout characteristics. Patient Related Outcome Measures, 2010, 2010, 1.	1.2	50
147	Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis and Rheumatism, 2006, 54, 1105-1116.	6.7	49
148	Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology, 2010, 49, 1184-1188.	1.9	49
149	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
150	Prevalence and correlates of sleep disturbance in systemic sclerosisresults from the UCLA scleroderma quality of life study. Rheumatology, 2011, 50, 1280-1287.	1.9	48
151	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clinical Rheumatology, 2014, 33, 207-214.	2.2	48
152	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	3.4	48
153	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology, 2010, 49, 955-959.	1.9	47
154	Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trialresults from the Scleroderma Lung Study. Rheumatology, 2009, 48, 1537-1540.	1.9	46
155	Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Journal of Rheumatology, 2011, 38, 1920-1924.	2.0	46
156	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clinical and Experimental Rheumatology, 2011, 29, S22-5.	0.8	46
157	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. Current Rheumatology Reports, 2009, 11, 111-119.	4.7	45
158	GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. Digestive Diseases and Sciences, 2014, 59, 2488-2496.	2.3	45
159	Old medications and new targeted therapies in systemic sclerosis. Rheumatology, 2015, 54, 1944-1953.	1.9	45
160	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. Journal of Rheumatology, 2019, 46, 721-726.	2.0	45
161	Validation of single-factor structure and scoring protocol for the health assessment questionnaire-disability index. Arthritis and Rheumatism, 2005, 53, 536-542.	6.7	44
162	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Research and Therapy, 2014, 16, 493.	3.5	44

#	Article	IF	CITATIONS
163	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 912-919.	5.6	44
164	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2009, 36, 2356-2361.	2.0	43
165	Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. Rheumatology, 2017, 56, 1970-1981.	1.9	43
166	Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.7	43
167	Interaction betweenRANKL andHLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis and Rheumatism, 2004, 50, 3093-3103.	6.7	42
168	Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosisassessment of individual body sites in two large randomized controlled trials. Rheumatology, 2009, 48, 1143-1146.	1.9	42
169	Systemic sclerosis trial design moving forward. Journal of Scleroderma and Related Disorders, 2016, 1, 177-180.	1.7	42
170	Pharmacokinetic optimitzation of CCC-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1744-1749.	2.2	42
171	Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell Reports Medicine, 2020, 1, 100140.	6.5	42
172	Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology, 2014, 53, 704-713.	1.9	41
173	Emerging strategies for treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 186-193.	1.7	41
174	Assessment of skin involvement in systemic sclerosis. Rheumatology, 2017, 56, v53-v66.	1.9	41
175	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. European Respiratory Journal, 2019, 54, 1900586.	6.7	41
176	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
177	Improved Transplantâ€Free Survival in Patients With Systemic Sclerosis–Associated Pulmonary Hypertension and Interstitial Lung Disease. Arthritis and Rheumatology, 2014, 66, 1900-1908.	5.6	40
178	Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis and Rheumatism, 2005, 52, 2284-2292.	6.7	39
179	Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. Journal of Rheumatology, 2011, 38, 990-996.	2.0	39
180	Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis. Arthritis and Rheumatism, 2013, 65, 2917-2927.	6.7	39

#	Article	IF	CITATIONS
181	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. Journal of Rheumatology, 2015, 42, 2460-2464.	2.0	39
182	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 2019, 78, 1242-1248.	0.9	39
183	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	3.8	39
184	Measuring Process of Arthritis Care: The Arthritis Foundation's Quality Indicator Set for Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2006, 35, 211-237.	3.4	38
185	Preventing Tuberculosis Flare in Patients with Inflammatory Rheumatic Diseases Receiving Tumor Necrosis Factor-α Inhibitors in India — An Audit Report. Journal of Rheumatology, 2009, 36, 1414-1420.	2.0	38
186	Screening Highâ€Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. Arthritis and Rheumatology, 2018, 70, 971-972.	5.6	38
187	Management of systemic sclerosis: the first five years. Current Opinion in Rheumatology, 2020, 32, 228-237.	4.3	38
188	Expansion of Fcγ Receptor <scp>Illa</scp> –Positive Macrophages, Ficolin 1–Positive <scp>Monocyteâ€Derived</scp> Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 329-341.	5.6	38
189	pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight, 2018, 3, .	5.0	38
190	The disutility of chronic gout. Quality of Life Research, 2008, 17, 815-822.	3.1	37
191	Taking Charge of Systemic Sclerosis: A Pilot Study to Assess the Effectiveness of an Internet Selfâ€Management Program. Arthritis Care and Research, 2014, 66, 778-782.	3.4	37
192	Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S169-S177.	3.2	37
193	The patient experience of Raynaud's phenomenon in systemic sclerosis. Rheumatology, 2019, 58, 18-26.	1.9	37
194	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
195	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192.	2.3	36
196	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213022.	0.9	36
197	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1892-1896.	5.6	36
198	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. Annals of the Rheumatic Diseases, 2016, 75, 1367-1371.	0.9	35

#	Article	IF	CITATIONS
199	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open, 2019, 5, e000826.	3.8	35
200	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
201	Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. Current Treatment Options in Rheumatology, 2020, 6, 337-353.	1.4	35
202	Understanding Gastrointestinal Distress: A Framework for Clinical Practice. American Journal of Gastroenterology, 2011, 106, 380-385.	0.4	34
203	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry, 2019, 62, 4350-4369.	6.4	34
204	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Seminars in Arthritis and Rheumatism, 2019, 48, 686-693.	3.4	34
205	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
206	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.7	33
207	Randomized Controlled Trial to Evaluate an Internetâ€Based Selfâ€Management Program in Systemic Sclerosis. Arthritis Care and Research, 2019, 71, 435-447.	3.4	33
208	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Arthritis Research and Therapy, 2019, 21, 23.	3.5	33
209	Arthritis in Systemic Sclerosis: Systematic Review of the Literature and Suggestions for the Performance of Future Clinical Trials in Systemic Sclerosis Arthritis. Seminars in Arthritis and Rheumatism, 2012, 41, 801-814.	3.4	32
210	Evaluation of Test Characteristics for Outcome Measures Used in Raynaud's Phenomenon Clinical Trials. Arthritis Care and Research, 2013, 65, 630-636.	3.4	32
211	Systemic sclerosis. Current Opinion in Rheumatology, 2015, 27, 241-248.	4.3	32
212	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 1453-1460.	0.9	32
213	Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clinical and Experimental Rheumatology, 2010, 28, S55-62.	0.8	32
214	Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology, 2011, 50, 1331-1336.	1.9	31
215	Connective Tissue Disease–Associated Interstitial Pneumonia and Idiopathic Interstitial Pneumonia: Similarity and Difference. Seminars in Ultrasound, CT and MRI, 2014, 35, 29-38.	1.5	31
216	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patientâ€Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. ACR Open Rheumatology, 2020, 2, 362-370.	2.1	31

#	Article	IF	CITATIONS
217	Fatigue and Its Association With Social Participation, Functioning, and Quality of Life in Systemic Sclerosis. Arthritis Care and Research, 2021, 73, 415-422.	3.4	31
218	Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Annals of the Rheumatic Diseases, 2007, 66, 1633-1640.	0.9	30
219	Development of Criteria for Evaluating Clinical Response in Thyroid Eye Disease Using a Modified Delphi Technique. JAMA Ophthalmology, 2009, 127, 1155.	2.4	30
220	Adverse Events during the Scleroderma Lung Study. American Journal of Medicine, 2011, 124, 459-467.	1.5	30
221	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. European Respiratory Review, 2013, 22, 515-525.	7.1	30
222	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology, 2015, 54, 144-151.	1.9	30
223	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2019, 48, 1059-1067.	3.4	30
224	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Doubleâ€Blind, Placebo ontrolled Trial. Arthritis and Rheumatology, 2021, 73, 1523-1532.	5.6	30
225	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Research and Therapy, 2021, 23, 170.	3.5	30
226	Treatment of early diffuse systemic sclerosis skin disease. Clinical and Experimental Rheumatology, 2013, 31, 166-71.	0.8	30
227	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care and Research, 2010, 62, 1772-1778.	3.4	29
228	Gender and ethnicity differences in patients with diffuse systemic sclerosisanalysis from three large randomized clinical trials. Rheumatology, 2011, 50, 335-342.	1.9	29
229	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respiratory Medicine, 2017, 122, S14-S17.	2.9	29
230	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Current Rheumatology Reviews, 2010, 6, 138-144.	0.8	28
231	Outcome Measures in Acute Gout: A Systematic Literature Review. Journal of Rheumatology, 2014, 41, 558-568.	2.0	28
232	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. ACS Pharmacology and Translational Science, 2019, 2, 92-100.	4.9	28
233	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opinion on Investigational Drugs, 2021, 30, 635-652.	4.1	28
234	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clinical and Experimental Rheumatology, 2012, 30, S23-9.	0.8	28

#	Article	IF	CITATIONS
235	Outcome evaluations in gout. Journal of Rheumatology, 2007, 34, 1381-5.	2.0	28
236	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Quality of Life Research, 2006, 15, 1383-1394.	3.1	27
237	Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Medical Decision Making, 2008, 28, 926-937.	2.4	27
238	Work productivity in scleroderma: Analysis from the University of California, Los Angeles scleroderma quality of life study. Arthritis Care and Research, 2012, 64, 176-183.	3.4	27
239	Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology, 2017, 56, v38-v44.	1.9	27
240	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	5.6	27
241	Treatment for systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology, 2021, 33, 240-248.	4.3	27
242	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 569-573.	2.0	26
243	Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis. Arthritis Care and Research, 2014, 66, 1731-1739.	3.4	26
244	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 891-896.	3.4	26
245	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. Genome Medicine, 2021, 13, 35.	8.2	26
246	Longâ€Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Metaâ€Analyses of Randomized, Controlled Trials and Observational Registries. Arthritis and Rheumatology, 2021, 73, 837-847.	5.6	26
247	Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. Journal of Rheumatology, 2004, 31, 1686-92.	2.0	26
248	Predictors of doctorâ€rated and patientâ€rated gout severity: gout impact scales improve assessment. Journal of Evaluation in Clinical Practice, 2010, 16, 1244-1247.	1.8	25
249	A Delphi Exercise to Identify Characteristic Features of Gout — Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. Journal of Rheumatology, 2013, 40, 498-505.	2.0	25
250	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. American Journal of Gastroenterology, 2014, 109, 234-248.	0.4	25
251	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgraduate Medicine, 2016, 128, 34-40.	2.0	25
252	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. Journal of Scleroderma and Related Disorders, 2017, 2, 42-49.	1.7	25

#	Article	IF	CITATIONS
253	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS ONE, 2018, 13, e0189498.	2.5	25
254	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 723-733.	3.4	25
255	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 641-650.	0.9	25
256	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
257	Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study. Quality of Life Research, 2011, 20, 1131-1140.	3.1	24
258	Construct Validity of the Patientâ€Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis. Arthritis Care and Research, 2014, 66, 1725-1730.	3.4	24
259	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Preference and Adherence, 2015, 9, 971.	1.8	24
260	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. American Journal of Gastroenterology, 2016, 111, 1546-1556.	0.4	24
261	Patientâ€Reported Outcomes From a Two‥ear Headâ€ŧoâ€Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 907-913.	3.4	24
262	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology, 2016, 55, 745-754.	1.9	24
263	Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clinical Immunology, 2011, 141, 293-303.	3.2	23
264	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. Journal of Rheumatology, 2013, 40, 1706-1711.	2.0	23
265	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. Journal of Investigative Dermatology, 2015, 135, 3153-3162.	0.7	23
266	Using Optimal Test Assembly Methods for Shortening Patientâ€Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scaleâ€6: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1704-1713.	3.4	23
267	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. Seminars in Arthritis and Rheumatism, 2016, 45, 439-445.	3.4	23
268	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v27-v32.	1.9	23
269	Points to consider—Raynaud's phenomenon in systemic sclerosis. Rheumatology, 2017, 56, v45-v48.	1.9	23
270	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. Journal of Rheumatology, 2019, 46, 1316-1325.	2.0	23

#	Article	IF	CITATIONS
271	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. Journal of Rheumatology, 2019, 46, 176-183.	2.0	23
272	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clinical and Experimental Rheumatology, 2010, 28, S42-6.	0.8	23
273	Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. Journal of Rheumatology, 2005, 32, 1040-2.	2.0	22
274	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology, 2015, 54, 1369-1379.	1.9	21
275	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology, 2018, 57, 813-817.	1.9	21
276	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Research and Therapy, 2019, 21, 202.	3.5	21
277	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. Arthritis and Rheumatology, 2021, 73, 520-529.	5.6	21
278	Predictive Significance of Serum Interferonâ€Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 1005-1013.	5.6	21
279	Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	5.6	21
280	Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat. Postgraduate Medicine, 2014, 126, 65-75.	2.0	20
281	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. Arthritis Research and Therapy, 2014, 16, 411.	3.5	20
282	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Annals of the Rheumatic Diseases, 2018, 77, 128-132.	0.9	20
283	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2021, 73, 1731-1737.	5.6	20
284	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	6.5	20
285	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: A systematic review. Seminars in Arthritis and Rheumatism, 2014, 43, 536-541.	3.4	19
286	Characterisation of an epigenetically altered CD4 ⁺ CD28 ⁺ Kir ⁺ T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. Lupus Science and Medicine, 2016, 3, e000147.	2.7	19
287	Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire. Arthritis Care and Research, 2013, 65, 454-463.	3.4	18
288	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	3.5	18

#	Article	IF	CITATIONS
289	Performance of Anti–Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. Journal of Clinical Rheumatology, 2020, 26, 115-118.	0.9	18
290	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 10.	3.5	18
291	Willingness to Pay for a Cure in Patients with Chronic Gout. Medical Decision Making, 2008, 28, 606-613.	2.4	17
292	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. Journal of Rheumatology, 2015, 42, 1624-1630.	2.0	17
293	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. Arthritis Care and Research, 2018, 70, 1653-1660.	3.4	17
294	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research and Therapy, 2019, 21, 8.	3.5	17
295	Identification of Cysteineâ€Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. Arthritis and Rheumatology, 2019, 71, 1350-1359.	5.6	16
296	COX-2 controversy: where are we and where do we go from here?. Inflammopharmacology, 2005, 13, 395-402.	3.9	15
297	Sclerodermadeveloping measures of response. Journal of Rheumatology, 2005, 32, 2477-80.	2.0	15
298	Systemic Sclerosis. Journal of Clinical Rheumatology, 2015, 21, 149-155.	0.9	14
299	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. Journal of Rheumatology, 2017, 44, 791-794.	2.0	14
300	Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology, 2017, 56, 103-112.	1.9	14
301	Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. International Journal of Rheumatic Diseases, 2019, 22, 1036-1040.	1.9	14
302	Using Transitional Changes on Highâ€Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis–Related Interstitial Lung Disease. Arthritis and Rheumatology, 2020, 72, 316-325.	5.6	14
303	Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?. Rheumatology, 2020, 59, 464-466.	1.9	14
304	Patient-reported outcome instruments in clinical trials of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 90-102.	1.7	14
305	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.7	14
306	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	3.4	13

#	Article	IF	CITATIONS
307	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v17-v22.	1.9	13
308	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology, 2018, 57, 152-157.	1.9	13
309	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
310	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease — Scleroderma Clinical Trials Consortium. Journal of Rheumatology, 2019, 46, 78-84.	2.0	13
311	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument. Arthritis Research and Therapy, 2020, 22, 3.	3.5	13
312	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. Rheumatology, 2021, 60, 5002-5011.	1.9	13
313	Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clinical and Experimental Rheumatology, 2013, 31, 57-63.	0.8	13
314	Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 146-149.	0.8	13
315	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 2022, 62, 234-242.	1.9	13
316	Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 550-557.	2.0	12
317	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. Rheumatology, 2016, 55, 982-990.	1.9	12
318	Points to consider in renal involvement in systemic sclerosis. Rheumatology, 2017, 56, v49-v52.	1.9	12
319	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis–associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 1295-1298.	2.0	12
320	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.7	12
321	Fatigue predicts future reduced social participation, not reduced physical function or quality of life in people with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 187-193.	1.7	12
322	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. Clinical Rheumatology, 2021, 40, 1611-1616.	2.2	12
323	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. JAMA Dermatology, 2021, 157, 851-858.	4.1	12
324	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰,✰,â~,â~ Seminars in Arthritis and Rheumatism, 2022, 52, 151926.	3.4	12

#	Article	IF	CITATIONS
325	Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. Statistical Methods in Medical Research, 2007, 16, 13-29.	1.5	11
326	Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, 2020, 59, 2156-2158.	1.9	11
327	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology, 2021, 60, 489-491.	1.9	11
328	Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial. Rheumatology, 2022, 61, 4397-4408.	1.9	11
329	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight, 2022, 7, .	5.0	11
330	Validating and Assessing the Sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in Patients with Early Aggressive Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 1150-1157.	2.0	10
331	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. Journal of Scleroderma and Related Disorders, 2017, 2, S29-S35.	1.7	10
332	Brief Report: Wholeâ€Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. Arthritis and Rheumatology, 2018, 70, 1654-1660.	5.6	10
333	Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future Directions. Arthritis Care and Research, 2022, 74, 59-69.	3.4	10
334	Genomeâ€Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin. Arthritis and Rheumatology, 2021, 73, 1501-1513.	5.6	10
335	Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. Journal of Rheumatology, 2008, 35, 466-8.	2.0	10
336	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes—Methodology and Preliminary Results. International Journal of Rheumatology, 2010, 2010, 1-7.	1.6	9
337	An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. Rheumatology International, 2012, 32, 2725-2729.	3.0	9
338	Autologous Hematopoietic Stem Cell Therapy in Severe Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2485.	7.4	9
339	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. Rheumatology, 2017, 56, v23-v26.	1.9	9
340	Factors influencing patient decisionâ€making concerning treatment escalation in Raynaud's phenomenon secondary to systemic sclerosis. Arthritis Care and Research, 2021, 73, 1845-1852.	3.4	9
341	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders, 2022, 7, 168-178.	1.7	9
342	<scp>Adiposeâ€Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis and Rheumatology, 2022, 74, 1399-1408.	5.6	9

#	Article	IF	CITATIONS
343	Health care utilization in patients with gout: a prospective multicenter cohort study. BMC Musculoskeletal Disorders, 2017, 18, 233.	1.9	8
344	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. Current Treatment Options in Rheumatology, 2019, 5, 85-103.	1.4	8
345	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. Clinical Rheumatology, 2020, 39, 93-102.	2.2	8
346	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study. Journal of Scleroderma and Related Disorders, 2021, 6, 154-164.	1.7	8
347	Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. Journal of Rheumatology, 2008, 35, 1966-71.	2.0	8
348	Quality indicator set for systemic sclerosis. Clinical and Experimental Rheumatology, 2011, 29, S33-9.	0.8	8
349	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Research and Therapy, 2022, 24, 19.	3.5	8
350	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology, 2022, 61, 4155-4162.	1.9	8
351	Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clinical and Experimental Rheumatology, 2011, 29, S15-21.	0.8	8
352	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. Clinical and Experimental Rheumatology, 2021, 39, 43-51.	0.8	8
353	Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation. IScience, 2022, 25, 104669.	4.1	8
354	Gouty tophi in a pancreatic pseudocyst. Arthritis and Rheumatism, 2002, 46, 565-566.	6.7	7
355	Valuation of scleroderma and psoriatic arthritis health states by the general public. Health and Quality of Life Outcomes, 2010, 8, 112.	2.4	7
356	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal of Medical Case Reports, 2015, 9, 136.	0.8	7
357	Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1032-1033.	5.6	7
358	Response to: †Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by NarvÃjez. Annals of the Rheumatic Diseases, 2019, 78, e124-e124.	0.9	7
359	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 66-76.	1.7	7
360	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. Expert Opinion on Emerging Drugs, 2020, 25, 455-466.	2.4	7

#	Article	IF	CITATIONS
361	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. Journal of Scleroderma and Related Disorders, 2020, 5, 167-171.	1.7	7
362	Racial Disparities in Systemic Sclerosis: Short―and Longâ€Term Outcomes Among African American Participants of SLS I and II. ACR Open Rheumatology, 2021, 3, 8-16.	2.1	7
363	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. Clinical Rheumatology, 2021, 40, 965-971.	2.2	7
364	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open, 2021, 11, e048541.	1.9	7
365	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. Clinical and Experimental Rheumatology, 2015, 33, S117-22.	0.8	7
366	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 106-113.	0.8	7
367	Chapter 5 Gastrointestinal Involvement in Systemic Sclerosis. Handbook of Systemic Autoimmune Diseases, 2008, 8, 51-61.	0.1	6
368	Points to consider when doing a trial primarily involving the heart. Rheumatology, 2017, 56, v12-v16.	1.9	6
369	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. Rheumatology, 2017, 56, v4-v11.	1.9	6
370	Management of systemic sclerosisâ€associated interstitial lung disease in the current era. International Journal of Rheumatic Diseases, 2020, 23, 137-139.	1.9	6
371	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. BMJ Open, 2021, 11, e044765.	1.9	6
372	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
373	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. Lancet Respiratory Medicine,the, 2021, 9, 560-562.	10.7	6
374	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	1.9	6
375	Capillary Proliferation in Systemicâ€6clerosisâ€Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. ACR Open Rheumatology, 2019, 1, 26-36.	2.1	5
376	A case of recalcitrant linear morphea responding to subcutaneous abatacept. Journal of Scleroderma and Related Disorders, 2021, 6, 194-198.	1.7	5
377	Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome. Journal of Rheumatology, 2002, 29, 1548-50.	2.0	5
378	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis. Frontiers in Immunology, 2022, 13, 814533.	4.8	5

#	Article	IF	CITATIONS
379	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology, 0, , .	1.9	5
380	Ayurvedic medicine: It is ?time? for scientifically sound studies. Seminars in Arthritis and Rheumatism, 2005, 34, 703-704.	3.4	4
381	Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations. Current Rheumatology Reviews, 2010, 6, 145-150.	0.8	4
382	Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: A baseline analysis. Contemporary Clinical Trials, 2011, 32, 160-168.	1.8	4
383	Examining radiographic outcomes over time. Rheumatology International, 2014, 34, 271-279.	3.0	4
384	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology, 2017, 56, v33-v37.	1.9	4
385	UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1422-1426.	2.0	4
386	Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. Lancet Rheumatology, The, 2021, 3, e463-e465.	3.9	4
387	Management of scleroderma gastrointestinal disease: Lights and shadows. Journal of Scleroderma and Related Disorders, 2022, 7, 85-97.	1.7	4
388	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. Arthritis Care and Research, 2012, 64, n/a-n/a.	3.4	3
389	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	2.0	3
390	Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders, 2016, 1, 7-9.	1.7	3
391	A randomized controlled trial of acupressure for the treatment of Raynaud's phenomenon: the difficulty of conducting a trial in Raynaud's phenomenon. Journal of Scleroderma and Related Disorders, 2016, 1, 226-233.	1.7	3
392	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. Journal of Rheumatology, 2016, 43, 1832-1837.	2.0	3
393	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	4.3	3
394	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study. Journal of Scleroderma and Related Disorders, 2020, 5, 143-151.	1.7	3
395	Development and Pilot Testing of MyGoutCare. Journal of Clinical Rheumatology, 2020, 26, 320-326.	0.9	3
396	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 963-967.	3.4	3

1

#	Article	IF	CITATIONS
397	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). Rheumatology Advances in Practice, 2021, 5, rkab027.	0.7	3
398	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, , .	3.4	3
399	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care and Research, 2021, , .	3.4	3
400	Assessing disease activity and outcome in scleroderma. , 2011, , 1367-1371.		3
401	Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2022, 7, 110-116.	1.7	3
402	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multiâ€center USâ€based longitudinal registry. International Journal of Rheumatic Diseases, 2022, 25, 163-174.	1.9	3
403	Cognitive difficulties in people with systemic sclerosis: a qualitative study. Rheumatology, 2022, 61, 3754-3765.	1.9	3
404	A Randomized Study of Scleroderma Health State Values: A Picture Is Worth a Thousand Words, and Quite a Few Utilities. Medical Decision Making, 2009, 29, 7-14.	2.4	2
405	Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry. Thorax, 2014, 69, 205-206.	5.6	2
406	Development of a Musculoskeletal Ultrasound Protocol to Examine Upper Extremity Rehabilitation Outcomes in Systemic Sclerosis. Journal of Diagnostic Medical Sonography, 2021, 37, 13-23.	0.3	2
407	The association between hand disease severity and fatigue in individuals with systemic sclerosis: a scoping review. Disability and Rehabilitation, 2022, 44, 5827-5833.	1.8	2
408	Clinical Outcome Measures in Raynaud's Phenomenon. , 2015, , 279-286.		2
409	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. ACR Open Rheumatology, 2022, 4, 596-602.	2.1	2
410	The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. Clinical Rheumatology, 2022, , .	2.2	2
411	Practical management of Raynaud's phenomenon – a primer for practicing physicians. Current Opinion in Rheumatology, 2022, 34, 235-244.	4.3	2
412	Diagnosis and management of systemic sclerosis. Indian Journal of Rheumatology, 2010, 5, 69-75.	0.4	1
413	Small and Large Intestinal Involvement. , 2012, , 485-499.		1

Treatment of Interstitial Lung Disease. , 2012, , 421-427.

#	Article	IF	CITATIONS
415	Measuring Disease Activity and Outcomes in Clinical trials. , 2012, , 661-671.		1
416	Health-Related Quality of Life and Outcome Measures in Gout. , 2012, , 217-225.		1
417	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e321-e323.	3.9	1
418	A 54-Year Old Woman with Pain and Stiffness of Hands and Tendon Friction Rubs. , 2011, , 267-271.		1
419	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 49-56.	0.8	1
420	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon. , 2009, , 77-95.		0
421	Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. Clinical Trials, 2010, 7, 85-89.	1.6	0
422	Dr. Malaviya, <i>et al</i> reply. Journal of Rheumatology, 2010, 37, 673-673.	2.0	0
423	Dr. Malaviya, et al reply. Journal of Rheumatology, 2010, 37, 1543.1-1543.	2.0	0
424	Il Buono, Il Brutto, Il Cattivo. Thorax, 2014, 69, 871-872.	5.6	0
425	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. Journal of Rheumatology, 2017, 44, 795-798.	2.0	0
426	Response to â€~Screening for Pulmonary Hypertension in Scleroderma'. Journal of Scleroderma and Related Disorders, 2017, 2, e6-e6.	1.7	0
427	207â€fCorrelation of the American College of Rheumatology provisional composite response index in systemic sclerosis with serum biomarkers of fibrogenesis in an observational cohort. Rheumatology, 2018, 57, .	1.9	Ο
428	FRI0310â€UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL TRACT 2.0 REFLUX-SCALE ASSOCIATES WITH IMPAIRED ESOPHAGEAL SCINTIGRAPHY FINDINGS IN SYSTEMIC SCLEROSIS. , 2019, , .		0
429	Reply. Arthritis and Rheumatology, 2019, 71, 327-328.	5.6	Ο
430	Response to: â€~Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. Annals of the Rheumatic Diseases, 2022, 81, e117-e117.	0.9	0
431	Gastrointestinal Involvement in Systemic Sclerosis. , 2014, , 77-87.		0
432	Assessing disease activity and outcome in systemic sclerosis (scleroderma). , 2015, , 1159-1164.		0

#	Article	IF	CITATIONS
433	Measuring Disease Activity and Outcomes in Clinical Trials. , 2017, , 637-648.		Ο
434	Interpretation of PFTs and Decline in PFTs. In Clinical Practice, 2021, , 139-149.	0.0	0
435	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 43-51.	0.8	0